Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome

Journal of Experimental Medicine

Volumn 185, Issue 1, 1997, Pages 65-70

  Santiago, Marie Laure ^a   Fossati, Liliane ^b   Jacquet, Chantal ^a   Müller, Werner ^c   Izui, Shozo ^b   Reininger, Luc ^a,d  

^a INSERM   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF COLOGNE   (Germany)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNITY; CELL DIFFERENTIATION; GENE LOCATION; GENETIC LINKAGE; GRAFT REJECTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; Y CHROMOSOME;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODY FORMATION; B-LYMPHOCYTES; CELL DIFFERENTIATION; ENHANCER ELEMENTS (GENETICS); ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; INTERLEUKIN-4; LUPUS NEPHRITIS; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); T-LYMPHOCYTES; TH2 CELLS;

EID: 0031036084     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.185.1.65     Document Type: Article

References (35)

1. Andrews, B.S., R.A. Eisenberg, A.N. Theofilopoulos, S. Izui, C.B. Wilson, P.J. McConahey, E.D. Murphy, J.B. Roths, and F.J. Dixon. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1198-1215.
2. Theofilopoulos, A.N. 1995. The basis of autoimmunity. I. Mechanisms of aberrant self-recognition. Immunol. Today. 16: 90-98.
3. Paul, W.E., and R.A. Seder. 1994. Lymphocyte responses and cytokines. Cell. 76:241-251.
4. Hamaoka, T., and S. Ono. 1986. Regulation of B-cell differentiation. Annu. Rev. Immunol. 4:167-204.
5. Kishimoto, T. 1989. The biology of interleukin-6. Blood. 74: 1-10.
6. Rousset, F., E. Garcia, T. Defrance, C. Péronne, N. Vezzio, D.H. Hsu, R. Kastelein, K.W. Moore, and J. Banchereau. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA. 89:1890-1893.
7. Goldman, M., P. Druet, and E. Gleichmann. 1991. TH2 cells in systemic autoimmunity: insights from allogeneic diseases and chemically-induced autoimmunity. Immunol. Today. 12: 223-227.
8. Finck, B.K., B. Chan, and D. Wofsy. 1994. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest. 94:585-591.
9. Ishida, H., T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179:305-310.
10. Nisitani, S., T. Tsubata, M. Murakami, and T. Honjo. 1995. Administration of interleukin-5 or -10 activates peritoneal B-1 cells and induces autoimmune hemolytic anemia in anti-erythrocyte autoantibody-transgenic mice. Eur. J. Immunol. 25:3047-3052.
11. Izui, S., M. Higaki, D. Morrow, and R. Merino. 1988. The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW X C57BL/6)F1 male mice, but not in C57BL/6 male mice. Eur. J. Immunol. 18:911-915.
12. Izui, S., M. Iwamoto, L. Fossati, R. Merino, S. Takahashi, and N. Ibnou-Zekri. 1995. The Yaa gene model of systemic lupus erythematosus. Immunol. Rev. 144:137-156.
13. Müller, W., R. Kühn, and K. Rajewsky. 1991. Major histocompatibility complex class II hyperexpression on B cells in interleukin 4-transgenic mice does not lead to B cell proliferation and hypergammaglobulinemia. Eur. J. Immunol. 21: 921-925.
14. Rolink, A.G., F. Melchers, and R. Palacios. 1989. Monoclonal antibodies reactive with the mouse interleukin-5 receptor J. Exp. Med. 169:1693-1701.
15. Luzuy, S., J. Merino, H. Engers, S. Izui, and P.H. Lambert. 1986. Autoimmunity after induction of neonatal tolerance to alloantigens: role of B cell chimerism and F1 donor B cell activation. J. Immunol. 136:4420-4426.
16. Merino, R., L. Fossati, M. Lacour, R. Lemoine, M. Higaki, and S. Izui. 1992. H-2 linked control of the Yaa gene induced acceleration of lupus-like autoimmune disease in BXSB mice. Eur. J Immunol. 22:295-299.
17. Yoshiki, T., R.C. Mellors, M. Strand, and J.T. August. 1974. The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice. J. Exp. Med. 140:1011-1027.
18. Izui, S., P.J. McConahey, J.P. Clark, L.M. Hang, I. Hara, and F.J. Dixon. 1981. Retroviral gp70 immune complexes in NZB X NZW F2 mice with murine lupus nephritis. J. Exp. Med. 154:517-528.
19. Maruyama, N., F. Furukawa, Y. Nakai, Y. Sasaki, K. Ohta, S. Ozaki, S. Hirose, and T. Shirai. 1983. Genetic studies of autoimmunity in New Zealand mice. J. Immunol. 130:740-746.
20. Snapper, C.M., and W.E. Paul. 1987. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science (Wash. DC). 236:944-947.
21. Snapper, C.M., T.M. McIntyre, R. Mandler, L.M.T. Pecanha, F.D. Finkelman, A. Lees, and J.J. Mond. 1992. Induction of IgG3 secretion by interferon-γ: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J. Exp. Med. 175:1367-1371.
22. Leal, L.M.C.C., D.W. Moss, R. Kühn, W. Müller, and F.Y. Liew. 1993. Interleukin-4 transgenic mice of resistant background are susceptible to Leishmania major infection. Eur. J. Immunol. 23:566-569.
23. Sher, A., and R.L. Coffman. 1992. Regulation of immunity to parasites by cells and T cell-derived cytokines. Annu. Rev. Immunol. 10:385-409.
24. Takahashi, S., L. Fossati, M. Iwamoto, R. Merino, R. Motta, T. Kobayakawa, and S. Izui. 1996. Imbalance towards TH1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J. Clin. Invest. 97: 1597-1604.
25. Jacob, C.O., P.H. Van der Meide, and H.O. McDevitt, 1987. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to γ interferon. J. Exp. Med. 166:798-803.
26. Ozmen, L., D. Roman, M. Fountoulakis, G. Schmid, B. Ryffel, and G. Garotta. 1995. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with soluble interferon-γ receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25:6-12.
27. Berney, T., T. Fulpius, T. Shibata, L. Reininger, J. Van Snick, H. Shan, M. Weigert, A. Marshak-Rothstein, and S. Izui. 1992. Selective pathogenicity of murine rheumatoid factors of the cryoprecipitable IgG3 subclass. Int. Immunol. 4:93-99.
28. Fulpius, T., F. Spertini, L. Reininger, and S. Izui. 1993. Immunoglobulin heavy chain constant region determines the pathogenicity and the antigen-binding activity of rheumatoid factor. Proc. Natl. Acad. Sci. USA. 90:2345-2349.
29. Takahashi, S., M. Nose, J. Sasaki, T. Yamamoto, and M. Kyogoku. 1991. IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis. J. Immunol. 147:515-519.
30. Steinberg, B.J., P.A. Smathers, K. Frederiksen, and A.D. Steinberg. 1982. Ability of the xid gene to prevent autoimmunity in (NZU X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA. J. Clin. Invest. 70:587-597.
31. Erausquin, C., R. Merino, S. Izui, L. Fernandez-Sueiro, F. Saez, F. Fernandez, V. Rodriguez-Valverde, and J. Merino. 1995 Therapeutic effect of early thymic irradiation in (NZB X NZW)F1 mice, associated with a selective decrease in the levels of IgG3 and gp-70-anti-gp70 immune complexes. Cell. Immunol. 161:207-212.
32. Klinman, D.M., and A.D. Steinberg. 1995. Inquiry into murine and human lupus. Immunol. Rev. 144:157-193.
33. Reininger, L., T. Radaszkiewicz, M. Kosco, F. Melchers, and A.C. Rolink. 1992. Development of autoimmune disease in SCID mice populated with long-term in vitro proliferating (NZB X NZW)F1 pre-B cells. J. Exp. Med. 176: 1343-1353.
34. Herron, L.R., R.L. Coffman, M.W. Bond, and B.L. Kotzin. 1988. Increased autoantibody production by NZB/NZW B cells in response to IL-5. J. Immunol. 141:842-847.
35. Röcken, M., M. Racke, and E.M. Shevach. 1996. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today. 17:225-231.